Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q4 2021 call → NOWe need to determine if management describes a situation where a proven instance is being replicated now, with demand already identified at the destination, and this replication is large relative to the company. Let's examine the transcript for such a description. Key points: IQOS ILUMA launched in Japan and Switzerland. They are planning to roll out to more markets this year, mostly in H2. They mention "we plan to roll out gradually to more markets this year, mostly in H2." That is future, not currently being stood up. They also mention "we plan to add more markets in 2022" for VEEV, but timing subject to device availability. They also mention "we plan a number of launches over the coming quarters" for nicotine pouches. But these are plans, not current physical replication. What about the "new complementary technology" for low and middle income markets? They say "we plan to enhance our portfolio for future growth with the introduction of a new complementary technology towards the end of this year." That's future. What about the U.S. manufacturing? They are working on contingency plans, including domestic manufacturing, hope to resume supply in first half of 2023. That is not yet. What about the existing IQOS in many markets? They are expanding geographically, but that is ongoing. The question asks for a specific proven instance being replicated now. Consider the example of ILUMA in Japan and Switzerland. They say "the outstanding success since its launch in Japan and Switzerland" and "we plan to roll out gradually to more markets this year, mostly in H2." That is planned, not currently being stood up. They also mention "we have had to accelerate both the supply of TEREA consumable using airfreight and the conversion of our production line to support new market launches." That indicates they are preparing for new markets, but not yet launched. The demand at destination? They see success in Japan and Switzerland, but for new markets, they haven't identified specific demand yet; they are planning. What about the "low and middle income market" success in Egypt, etc.? They see promising growth, but they are not replicating a proven instance there; they are launching new products.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.